Literature DB >> 23434580

Akt kinase targets the association of CBP with histone H3 to regulate the acetylation of lysine K18.

Yan Liu1, Zhao-bin Xing, Jing-hua Zhang, Yue Fang.   

Abstract

CREB binding protein (CBP) is an acetyltransferase that plays an important role in many biological processes. Here, we show that Akt phosphorylates CBP at threonine 1871 and suppresses its acetyltransferase activity by impeding the binding of CBP to histone H3, which results in a decrease in lysine K18 acetylation and dysregulation of target genes. Our results demonstrate that Akt regulates acetyltransferase activity through CBP phosphorylation, which may contribute to tumorigenesis.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434580     DOI: 10.1016/j.febslet.2013.02.023

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Signaling coupled epigenomic regulation of gene expression.

Authors:  R Kumar; S Deivendran; T R Santhoshkumar; M R Pillai
Journal:  Oncogene       Date:  2017-06-26       Impact factor: 9.867

Review 2.  The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.

Authors:  Jennifer M Spangle; Thomas M Roberts; Jean J Zhao
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-14       Impact factor: 10.680

3.  Germline or inducible knockout of p300 or CBP in skeletal muscle does not alter insulin sensitivity.

Authors:  Vitor F Martins; Jessica R Dent; Kristoffer Svensson; Shahriar Tahvilian; Maedha Begur; Shivani Lakkaraju; Elisa H Buckner; Samuel A LaBarge; Byron Hetrick; Carrie E McCurdy; Simon Schenk
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-03-19       Impact factor: 4.310

4.  Protein arginine methyltransferase 5 (PRMT5) promotes survival of lymphoma cells via activation of WNT/β-catenin and AKT/GSK3β proliferative signaling.

Authors:  Jihyun Chung; Vrajesh Karkhanis; Robert A Baiocchi; Saïd Sif
Journal:  J Biol Chem       Date:  2019-03-18       Impact factor: 5.157

5.  Histone modifications are associated with Δ9-tetrahydrocannabinol-mediated alterations in antigen-specific T cell responses.

Authors:  Xiaoming Yang; Venkatesh L Hegde; Roshni Rao; Jiajia Zhang; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Biol Chem       Date:  2014-05-19       Impact factor: 5.157

6.  PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.

Authors:  Mohamed Rahmani; Mandy Mayo Aust; Elisa C Benson; LaShanale Wallace; Jonathan Friedberg; Steven Grant
Journal:  Clin Cancer Res       Date:  2014-07-28       Impact factor: 12.531

7.  Acetylation-dependent regulation of essential iPS-inducing factors: a regulatory crossroad for pluripotency and tumorigenesis.

Authors:  Xiangpeng Dai; Pengda Liu; Alan W Lau; Yueyong Liu; Hiroyuki Inuzuka
Journal:  Cancer Med       Date:  2014-08-13       Impact factor: 4.452

8.  Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.

Authors:  Muyun Wei; Shaowei Mao; Guoliang Lu; Liang Li; Xiaopeng Lan; Zhongxian Huang; Yougen Chen; Miaoqing Zhao; Yueran Zhao; Qinghua Xia
Journal:  BMC Cancer       Date:  2018-04-17       Impact factor: 4.430

9.  p300 or CBP is required for insulin-stimulated glucose uptake in skeletal muscle and adipocytes.

Authors:  Vitor F Martins; Samuel A LaBarge; Alexandra Stanley; Kristoffer Svensson; Chao-Wei Hung; Omer Keinan; Theodore P Ciaraldi; Dion Banoian; Ji E Park; Christina Ha; Byron Hetrick; Gretchen A Meyer; Andrew Philp; Larry L David; Robert R Henry; Joseph E Aslan; Alan R Saltiel; Carrie E McCurdy; Simon Schenk
Journal:  JCI Insight       Date:  2022-01-11

10.  Differences in specificity and selectivity between CBP and p300 acetylation of histone H3 and H3/H4.

Authors:  Ryan A Henry; Yin-Ming Kuo; Andrew J Andrews
Journal:  Biochemistry       Date:  2013-08-12       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.